期刊文献+

一种人工合成Tuftsin类似肽大鼠组织分布和排泄研究 被引量:6

Biodistribution and Excretion of a Synthetic Tuftsin-Analog in Rats
下载PDF
导出
摘要 目的研究Tuftsin类似肽(T肽)单次皮下注射后在大鼠体内的组织分布特点和排泄情况。方法 Wistar大鼠,单次皮下注射剂量21.6 mg.kg-1T肽。采用竞争ELISA方法检测各时间点的组织器官、尿、粪和胆汁中的药物含量。结果组织分布试验结果表明,药物主要分布在大鼠的血清、肾、脾和小肠组织中,除小肠达峰时间为给药后2 h之外,其它药物含量均于给药后15 min达最高;排泄实验结果表明,0~144 h内尿和粪中排泄的原型药物分别占给药总量的2.21%和0.03%;0~96 h内大鼠胆汁中排泄的原型药物为给药总量的0.02%。结论 T肽给药后在Wistar大鼠体内广泛分布,在血清、肾和脾组织中含量较高,在粪和胆汁中检测出T肽的含量很少。 Objective To investigate the biodistribution and excretion of a Synthetic Tuftsin-Analog(T peptide) single subcutaneously administrated in rats.Methods Thirty rats were subcutaneously administered T peptide at a dose of 21.6 mg · kg-1.The T peptide levels in normal organs,urine,excrement and bile were determined by competitive ELISA method,respectively.Results T peptide was widely distributed in the tissues of rats.The concentration of T peptide in the serum,kidney,spleen and small intestine was high in rats,and reached the maximum at 15 min except for the small intestine at 2 h.The excretion of T peptide in the urine,excrement and bile amounted to 2.21%,0.03% and 0.02% of the dose,respectively.Conclusion T peptide is widely distributed in the tissues,especially in the serum,kidney and spleen.A small amount of T peptide is detected in the excrement and bile
出处 《解放军药学学报》 CAS 2013年第4期328-331,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 国家科技重大专项课题-"临床前药代动力学技术平台"资助 No.2012ZX09301003-001-007 国家自然基金资助 No.21104095
关键词 TUFTSIN T肽 组织分布 排泄 Tuftsin T peptide distribution excretion
  • 相关文献

参考文献8

  • 1Najjar VA,Nishioka K.Tuftsin:A natural phagocytosis stimulatingpeptide[J].Nature,1970,288(5272):672-673.
  • 2Timur K,Maria S,Lyudmila A,et al.Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank[J].Regulatory Peptides,2011,170(1-3):18-23.
  • 3Wardowska A,Dzierzbicka K,Trzonkowski P,et al.Immunomodu-latory properties of new conjugates of muramyl dipeptide and nor-muramyl dipeptide with retro-tuftsin(Arg-Pro-Lys-OMe)[J].In-ter Immunopharmacol,2006,6(10):1560-1568.
  • 4Ignacy ZS,Alicja K.Tuftsin:On the 30-year anniversary of VictorNajjaryS discovery[J].Peptides,1999,20(5):645-674.
  • 5Magdalena KK,Krystyna D,Zbigniew M.Synthesis of linear tuftsinanalogues modified at the e-amino group of lysine[J]? TetrahedronLetters,2008,49(40):5718-5710.
  • 6Xu YY,Zhu JD,Xiang Ky et al.Synthesis and immunomodulatoryactivity of[60]fullerene-tuftsin conjugates[J].Biomaterials,2011,32(36):9940-9949.
  • 7贾娜,李琳娜,杨德宣,王珊珊,袁守军.小鼠术后残瘤模型的建立及T肽抑制术后残瘤生长的初步研究[J].解放军药学学报,2010,26(5):377-380. 被引量:4
  • 8汪琼,贾娜,杨德宣,王珊珊,郭万军,袁守军.促吞噬肽衍生物T肽抑制小鼠移植瘤和术后残瘤生长的药效学研究[J].军事医学,2012,36(5):357-361. 被引量:8

二级参考文献12

  • 1Guo Hao Wu Yan Wei Zhang Zhao Han Wu Department of General Surgery.zhongshan Hospital,ShangHai Medical University.ShangHai 200032.China.Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients[J].World Journal of Gastroenterology,2001,7(3):357-362. 被引量:67
  • 2Nishioka K,Amoscato AA,Babcock GF. Tuftsin:an immunomodulating peptide hormone and its clinical potential as a natural biological response modifier[J].Cancer Investigation,1984,(01):39-49.
  • 3Najjar VA,Nishioka K. Tuftsin:a natural phagocytosis stimulating peptide[J].Nature,1970.672-673.
  • 4Fridkin M,Najjar VA. Tuftsin:its chemistry,biology,and clinical potential[J].Critical Reviews in Biochemistry and Molecular Biology,1989,(01):1-40.
  • 5Gajewski T F,Meng Y,Harlin H. Immune suppression in the tumor microenvimnment[J].Journal of Immunotherapy,2006,(03):233-240.
  • 6Reang P,Gupta M,Kohli K. Biological Response Modifiers in Cancer[J].Medscape General Medicine,2006,(04):33.
  • 7Murthy T,Janaki KS,Nagarjuna S. Biological Response Modifiers[J].Int J ChemTechRes,2010,(04):2152-2160.
  • 8Oldham RK. Biologicals and biological response modifiers:fourth modality of cancer treatment[J].Cancer Treatment Reports,1984,(01):221-232.
  • 9Dougan M,DranoffImmune G. Therapy for Cancer[J].Annual Review of Immunology,2009,(13):83-117.
  • 10Whiteside TL. The tumor microenvironment and its role in promoting tumor growth[J].Oncogene,2008,(01):5904-5912.

共引文献9

同被引文献29

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1368
  • 2赵娟(综述),邹萍(审校),陈智超(审校).巨噬细胞炎性蛋白-1α在多发性骨髓瘤发病机制中的作用[J].国际输血及血液学杂志,2007,30(6):540-542. 被引量:1
  • 3Najjar V A,Constantopoulos A.A new phagocytosis-stimulating tetrapeptide hormone,tuftsin,and its role in disease[J].J Reticuloendothel Soc,1972,12(2):197-215.
  • 4Najjar V A,Nishioka K.“Tuftsin”:a natural phagocytosis stimulating peptide[J].Nature,1970,228(5272):672-3.
  • 5Nishioka K.Anti-tumour effect of the physiological tetrapeptide,tuftsin[J].Br J Cancer,1979,39(3):342-5.
  • 6贾娜.小鼠术后残瘤模型的建立及T肽抑制术后残瘤生长的初步研究[D].北京:军事医学科学院,2010.
  • 7An Y,Li L,Yang D,et al.Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors[J].Anticancer Drugs,2014,25(8):857-67.
  • 8Mantovani A,Sozzani S,Locati M,et al.Macrophage polarization:tumor-associated macrophages as a paradigm for polarized M2mononuclear phagocytes[J].Trends Immunol,2002,23(11):549-55.
  • 9Mantovani A,Schioppa T,Porta C,et al.Role of tumor-associated macrophages in tumor progression and invasion.[J].Cancer Metastasis Rev,2006,25(3):315-22.
  • 10Hsu C J,Wu M H,Chen C Y,et al.AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma[J].Cell Commun Signal,2013,11(68):.

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部